Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unprecedented changes in human-environment interactions and increasing disruptions to ecosystems and the climate have contributed to the emergence of infectious diseases (Emerging Infectious Diseases, EIDs). Advances in the treatment of cancers, malignant haematological disorders and immune-mediated inflammatory diseases are also contributing to the creation of new infectious risks among immunocompromised patient populations.
The COVID-19 pandemic has shown that structuring research prior to any outbreak is essential for the rapid implementation of responses to the emergence of an EID. The unpredictability of an EID's occurrence necessitates the planning of research projects in advance. A key element in this planning is the development of a collection of biological samples, providing a structured and immediately deployable resource for conducting pathophysiological and therapeutic research aimed at:
COMETE consists in a prospective monocenter longitudinal non-interventional study allowing the collection of biological samples from individuals or patients investigated in the context of an emerging infectious disease or one at risk of emergence due to exposure or suggestive symptomatology, whether the infection is ultimately ruled out or confirmed, and whether or not they have received curative or preventive treatment for this infection.
Visits: The initial visit (inclusion) and follow-up visits will take place as part of the patient's routine care, assessing their disease status or the curative or preventive treatment received during either hospitalization or a consultation. During these visits, biological samples will be collected when sampling is planned as part of the care (for verification, suspicion, diagnosis, or monitoring), and then throughout the follow-up period as part of the care plan.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Subjects presenting with emerging or potentially emerging infectious diseases | Biological samples will be collected in the normal diagnosis and follow-up process (only blood will be collected in larger quantity) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Collection of biological samples and associated data from patients at risk of acquiring, or affected by, emerging or potentially emerging infectious diseases, including those receiving preventive or curative treatment for such infections | Prospective collection of all available biological and clinical-biological-imaging data collected during the usual clinical care | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| To improve our understanding of the pathophysiology of infection in order to identify new biomarkers for diagnostic and prognostic purposes, with a view to improving the management of emerging infectious diseases or those at risk of emerging | Identification of biomarkers using collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …) | through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Patients under a legal guardianship arrangement (guardianship, curatorship or court-ordered guardianship)
Not provided
Not provided
Patients presenting with emerging infectious disease
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guillaume MARTIN-BLONDEL, MD, PhD | Contact | +33561779699 | 33 | martin-blondel.g@chu-toulouse.fr |
| Béatrice PIGNOLET, PhD | Contact | +33561779975 | 33 | pignolet.b@chu-toulouse.fr |
| Name | Affiliation | Role |
|---|---|---|
| Guillaume MARTIN-BLONDEL, MD, PhD | University Hospital, Toulouse | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Toulouse | Toulouse | 31059 | France |
Not provided
| ID | Term |
|---|---|
| D021821 | Communicable Diseases, Emerging |
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, saliva, mucus, urine, faeces, semen, breast milk, colostrum, body hair, head hair, fingernails, sweat, tears Minimal supplementary volume of liquid/effusions carried out during a sampling and performed as part of the routine care Superficial swabbing of the skin, the nasal or pharyngeal mucosa, the oral cavity (including the oropharynx), and the ear canal Leftover of biological samples taken as part of the care process: cerebrospinal fluid, lung biopsy, placenta, vaginal or anal margin samples, tissue biopsies
| Identify new therapeutic targets for curative or preventive treatments | Identification of therapeutic targets using collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …) | through study completion, an average of 1 year |
| At the pathogen level: Analyse the biological determinants of the microbe and the resulting infection | Identification of biological determinants of the microbe and the resulting infection using collected biological samples with various methods of screening (PCR, qPCR, sequencing, metagenomics) | through study completion, an average of 1 year |
| At the pathogen level: Develop new tools for identification and characterisation | Use of the biological samples obtained from patients for using new and innovative methods of screening (PCR, qPCR, sequencing, metagenomics) | through study completion, an average of 1 year |
| At the host level: Identification and/or validation of associated or predictive biomarkers | Use of collected biological samples obtained from patients for cohort studies with various methods (flow cytometry, -omics, …) | through study completion, an average of 1 year |